Aegerion Pharmaceuticals Inc. (AEGR): Today's Featured Health Care Laggard

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

Aegerion Pharmaceuticals ( AEGR) pushed the Health Care sector lower today making it today's featured Health Care laggard. The sector as a whole closed the day up 0.7%. By the end of trading, Aegerion Pharmaceuticals fell $2.58 (-3.6%) to $69.47 on average volume. Throughout the day, 585,165 shares of Aegerion Pharmaceuticals exchanged hands as compared to its average daily volume of 661,900 shares. The stock ranged in price between $69.10-$72.05 after having opened the day at $72.05 as compared to the previous trading day's close of $72.05. Other companies within the Health Care sector that declined today were: Dynavax Technologies Corporation ( DVAX), down 13.0%, Rexahn Pharmaceuticals ( RNN), down 12.8%, Echo Therapeutics ( ECTE), down 12.7% and Cornerstone Therapeutics ( CRTX), down 11.4%.
  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass

Aegerion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of novel therapeutics to treat debilitating and fatal rare diseases in the United States. Aegerion Pharmaceuticals has a market cap of $2.1 billion and is part of the drugs industry. Shares are up 191.6% year to date as of the close of trading on Wednesday. Currently there are 12 analysts that rate Aegerion Pharmaceuticals a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates Aegerion Pharmaceuticals as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income and feeble growth in its earnings per share.

On the positive front, USMD Holdings ( USMD), down 17.1%, Verastem ( VSTM), down 13.9%, Savient Pharmaceuticals ( SVNT), down 12.7% and Delcath Systems ( DCTH), down 10.6% , were all gainers within the health care sector with Merck ( MRK) being today's featured health care sector leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you liked this article you might like

5 Stocks Insiders Love Right Now

7 Stocks Under $10 Making Big Up Moves

5 Stocks Under $10 Set to Soar

Wall Street Loses Gains After Fed's Unsurprising June Call

Stocks Turn Lower After Yellen Expresses Confidence in U.S. Economy